DPDavid M. Peng

David M. Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David M. Peng has a total of 386 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characteristics associated with elevated dd-cfDNA in pediatric heart transplant recipients without rejection by biopsy

    by Sonali Verma, Sunkyung Yu, Ashley Duimstra, Natalie Sinicropi, Bethany Giacobbe, Emily Dudley, Kurt R. Schumacher, Amanda D. McCormick, Heang Lim, David M. Peng

  • Predictors of Response to Cardiac Resynchronization Therapy in Pediatric Patients and Patients With Congenital Heart Disease

    by Henry Chubb, Douglas Mah, Maully Shah, Kimberly Y. Lin, David Peng, Benjamin W. Hale, Lindsay May, Susan Etheridge, William Goodyer, Scott R. Ceresnak, et al.

    BACKGROUND: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric patients and patients with congenital heart disease with reduced systemic ventricular ejection fraction (SVEF). However, the identification of optimal responders is challenging. This study aimed to identify predictors of response to CRT in children and patients with congenital heart disease at 5 large quaternary referral centers. METHODS: Patients were aged P =0.013), biventricular circulation ( P =0.022), systemic left ventricle ( P =0.021), and conduction delay to the lateral wall of the systemic ventricle ( P =0.01) were associated with a positive response. For the assessment of the secondary outcome, 324 controls were identified. Median follow-up is 5.1 (interquartile range, 2.0–8.6) years. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic right ventricle ( P =0.69) or without prior single-site pacemaker ( P =0.20). CONCLUSIONS: CRT in children and patients with congenital heart disease frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to the lateral wall of the systemic ventricle, and those with a systemic left ventricle are most likely to respond.


  • Open Access

    Donor‐Derived Cell‐Free DNA as a Marker for the Efficacy of Daratumumab in Patients With Antibody‐Mediated Rejection Post‐Heart Transplantation: A Case Series

    by Anusha Konduri, Kathryn E. Flynn, Ashley Huebschman, Bronwyn Crandall, Natalie Sinicropi, Bethany Giacobbe, Mary Zamberlan, Matthew Najor, Matthew Cusick, Heang M. Lim, et al.

    Background: Antibody‐mediated rejection (AMR) remains a significant complication following heart transplantation, contributing to graft dysfunction and reduced survival. Donor‐derived cell‐free DNA (dd‐cfDNA) is emerging as a non‐invasive biomarker for detecting and monitoring graft injury, correlating with episodes of rejection and response to treatment. Daratumumab, an anti‐CD38 monoclonal antibody targeting plasma cells, has shown promise in treating AMR. We present a case series of pediatric and young adult heart transplant recipients demonstrating donor‐derived cell‐free DNA's potential utility in monitoring for AMR and the effect of therapies including daratumumab. Case Descriptions: We report five cases showing that elevated dd‐cfDNA correlated with pathological AMR (pAMR), and treatment with daratumumab improved both pAMR and dd‐cfDNA levels. Most of our patients had persistently elevated donor‐specific antibody (DSA) as observed by MFI values; however, there was a reduction in DSA titer that corresponded with improvement in pAMR and dd‐cfDNA levels. Recurrent increases in dd‐cfDNA were also useful in guiding the need for repeat treatment with daratumumab. Although DSA levels often remained elevated despite histologic improvement, decreasing dd‐cfDNA levels correlated more closely with the resolution of AMR. Conclusion: In this case series of pediatric and young adult heart transplant recipients, our findings suggest that dd‐cfDNA can serve as a valuable biomarker for diagnosing AMR and treatment response, which are not often reflected by DSA MFI alone. Our dd‐cfDNA data supports the efficacy of daratumumab in treating AMR and may guide the need for ongoing treatment. Further studies are warranted to validate these findings and establish guidance for the use of daratumumab and dd‐cfDNA in this patient population.


  • Open Access

    Prostacyclin Therapy as Adjunctive Treatment for Pulmonary Hypertension in Pediatric Heart Transplantation: A Case Report

    by Anusha Konduri, Aly J. Sonnen, Heang M. Lim, Kurt R. Schumacher, David M. Peng, Vikram Sood, Mary K. Olive, Amanda D. McCormick

    Background: Elevated pulmonary vascular resistance is a significant risk factor for right‐ventricle failure and poor outcomes following pediatric heart transplantation. Pulmonary vasodilator therapy can help manage symptoms and improve heart transplant candidacy. While phosphodiesterase type 5 inhibitors and endothelin receptor antagonists are commonly used, prostacyclin therapy remains less studied in this context. Case Description: A 15‐year‐old female with Shone's complex developed heart failure with preserved ejection fraction and severe pulmonary hypertension. Given her indexed pulmonary vascular resistance (15 indexed wood units with vasodilator testing) on initial cardiac catheterizations was felt to be prohibitive to heart transplant, she was treated stepwise with tadalafil, ambrisentan, and selexipag. Serial cardiac catheterizations showed an improvement in her pulmonary vascular resistance as well as vasoreactivity of her pulmonary vasculature. She was listed for heart transplant and underwent transplantation with perioperative support including inhaled prostacyclin. Post‐operatively, her mean pulmonary artery pressure and pulmonary vascular resistance improved, though she later required a transition to subcutaneous treprostinil for recurrence of pulmonary hypertension with right‐ventricle failure despite only a mildly elevated left ventricle end‐diastolic pressure. Over the following year, her pulmonary pressures stabilized, and she was transitioned back to oral therapies and continued to do well at 1 year post‐transplantation. Conclusion: This case highlights that aggressive medical management, including prostacyclin therapy, can render even high‐risk pediatric patients with elevated pulmonary vascular resistance eligible for heart transplant and improve post‐operative outcomes. It supports emerging evidence that elevated pulmonary vascular resistance, particularly when responsive to vasodilators, should not be viewed as an absolute contraindication to heart transplantation and emphasizes the importance of tailored, ongoing pulmonary hypertension management in children with congenital heart disease.

  • Open Access

    Capturing Physiological Data in Children With Heart Failure Using Wearable Digital Technology: Lessons From Pilot Project

    by David M. Peng, Jonathan B. Edelson, Harishwara R. Gureddygari, Toni Duganiero, Aine Lynch, Melissa McQueen, Joseph Hillenburg, E. Kevin Hall, Lauren Smyth, David N. Rosenthal, et al.


  • The ACTION VAD registry: A collective five-year experience

    by Jonathan B Edelson, Alexander Raskin, Mohammed Absi, Iki Adachi, Othman Aljohani, Anaam Alzubi, Shahnawaz Amdani, Alfred Asante-Korang, Scott Auerbach, Neha Bansal, et al.


  • Open Access

    Predictors of Response to Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients

    by Henry Chubb, Douglas Y Mah, Maully J. Shah, Kimberly Yee Lin, David Ming-Shen Peng, Benjamin W Hale, Lindsay J May, Susan Etheridge, William Rowland Goodyer, Scott R Ceresnak, et al.

    Background: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. Objective: To identify predictors of response to CRT in children and CHD patients at 5 large quaternary referral centers. Methods: Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome utilized a propensity score-matched control cohort. Response to CRT was defined using longitudinal trajectory of SVEF up to latest follow-up. Results: In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged, 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and conduction delay to lateral wall of SV (p=0.01) were associated with positive response. For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7) yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic RV (p=0.69) or without prior single site pacemaker (p=0.20). Conclusion: CRT in children and CHD patients frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most likely to respond. Condensed Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were identified. The primary outcome was change in EF at 6/12months. Those with lower baseline SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond to CRT. When compared to propensity score-matched controls, the CRT groups also demonstrated a significantly better long-term EF trajectory.

  • Pediatric Learning Health Networks in Solid Organ Transplantation—Engaging all Stakeholders to Achieve Health for Children Who Require Transplantation

    by Roshan P. George, Amy G. Feldman, Melissa McQueen, Cassandra Krise‐Confair, Lauren Smyth, Angela Lorts, David M. Peng, George V. Mazariegos, David K. Hooper

    Background: Learning Health Networks (LHN) have evolved within medicine over the past two decades, but their integration into transplantation has been more recent.Objectives and Methods: In this paper, we describe three LHNs in end‐stage organ disease/transplantation, their common and unique features, and how their “actor‐oriented” architecture allowed for rapid adaptation to meet the needs of their patients and practitioners during the recent COVID‐19 pandemic.Result: The structure and focus of the Improving Renal Outcomes Collaborative (IROC), Starzl Network for Excellence in Pediatric Transplantation (SNEPT), and the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) are reviewed. We discuss the critical role of patient and family engagement, focusing on collaboration with Transplant Families. Finally, we review challenges common to the LHN concept and potential common areas of alignment to achieve the goal of more rapid and sustained progress to improve health in pediatric transplantation.Conclusion: LHN in transplantation are essential to accelerate knowledge dissemination and improve outcomes.


  • Top Cited Papers

    Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database

    by Ryan J. Butts, Leah Toombs, James K. Kirklin, Kurt R. Schumacher, Jennifer Conway, Shawn C. West, Scott Auerbach, Neha Bansal, Hong Zhao, Ryan S. Cantor, et al.

    BACKGROUND: Waitlist mortality (WM) remains elevated in pediatric heart transplantation. Allocation policy is a potential tool to help improve WM. This study aims to identify patients at highest risk for WM to potentially inform future allocation policy changes. METHODS: The Pediatric Heart Transplant Society database was queried for patients 0.7 m 2 BSA groups. VAD support was associated with lower WM other than in the single ventricle cohort, where VAD was associated with higher WM. Extracorporeal membrane oxygenation and mechanical ventilation were associated with increased risk of WM in all cohorts. CONCLUSIONS: There is significant variability in WM among status-1A patients. Potential refinements to current allocation system should factor in the increased WM risk we identified in patients supported by extracorporeal membrane oxygenation or mechanical ventilation, single ventricle congenital heart disease on VAD support and small children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopathy.


  • Social Determinants of Health and Outcomes After Pediatric Ventricular Assist Device Implantation

    by Caroline L. West, Hong Zhao, Ryan Cantor, Vikram Sood, Ashwin K. Lal, Claude Beaty, James K. Kirklin, David M. Peng

    Background: Limited research exists on the influence of social determinants of health (SDOH) on outcomes in pediatric patients with advanced heart failure receiving mechanical circulatory support.Methods: Linkage of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) and Society of Thoracic Surgeon's Congenital Heart Surgery Database (STS‐CHSD) identified pediatric patients who underwent ventricular assist device (VAD) implantation from 2012 to 2022 with available residential zip codes. Utilizing the available zip codes, each patient was assigned a Childhood Opportunity Index (COI) score. Level of childhood opportunity, race, and insurance type were used as proxies for SDOH. Major outcomes included death, transplant, alive with device, and recovery. Secondary outcomes were adverse events. Statistical analyses were performed using the Kaplan–Meier survival, competing risk analyses, and multivariable Cox proportional hazards model.Results: Three hundred seventeen patients were included in the study. Childhood opportunity level and insurance status did not significantly impact morbidity or mortality after VAD implantation. White race was associated with reduced 1‐year survival (71% in White vs. 87% in non‐White patients, p = 0.05) and increased risk of pump thrombosis (p = 0.02).Conclusion: Childhood opportunity level and insurance status were not linked to morbidity and mortality in pediatric patients after VAD implantation. Notably, White race was associated with higher mortality rates. The study underscores the importance of considering SDOH in evaluating advanced therapies for pediatric heart failure and emphasizes the need for accurate socioeconomic data collection in future studies and national registries.